Cite
HARVARD Citation
Battelino, T. et al. (2023). Continuous glucose monitoring‐based time‐in‐range using insulin glargine 300 units/ml versus insulin degludec 100 units/ml in type 1 diabetes: The head‐to‐head randomized controlled InRange trial. Diabetes, obesity & metabolism. 25 (2), pp. 545-555. [Online].